Stem Cell-based Therapies in Inflammatory Bowel Disease: Promises and Pitfalls

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2016 Jul 2

PMID 27366222

Citations 17

Authors

Natalie E Duran

Daniel W Hommes

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD) is a chronic, often relapsing, condition that deeply impacts the quality of life for many patients. Although there have been significant advances in medical treatments, a large proportion of patients become refractory to available therapeutic options. Stem-cell therapy through hematopoietic stem cells (HSCs) or mesenchymal stem (stromal) cells (MSCs) is a promising therapeutic option for severe refractory cases especially when surgery is not feasible. In HSC transplantation, the objective is to destroy the 'autoreactive' immune cells responsible for disease chronicity, and to re-establish gut tolerance to gut microbes. In perianal Crohn's disease (CD), the objective is to deposit MSCs locally in fistulizing tracts to down-regulate the local immune response and induce wound healing. Results from upcoming and ongoing clinical trials will set the path of these novel therapeutic options that have the capability to successfully treat severe refractory Crohn's patients.

Citing Articles

Comparison of Autologous and Allogeneic Adipose-Derived Stem Cells in Kidney Transplantation: Immunological Considerations and Therapeutic Efficacy.

Fodor Duric L, Basic Jukic N, Vujicic B J Clin Med. 2024; 13(19).

PMID: 39407823 PMC: 11476955. DOI: 10.3390/jcm13195763.

Comparison of different sources of mesenchymal stem cells: focus on inflammatory bowel disease.

Shi L, Chen L, Gao X, Sun X, Jin G, Yang Y Inflammopharmacology. 2024; 32(3):1721-1742.

PMID: 38615278 DOI: 10.1007/s10787-024-01468-1.

Advances in the Treatment of Kidney Disorders using Mesenchymal Stem Cells.

Rajput S, Malviya R, Uniyal P Curr Pharm Des. 2024; 30(11):825-840.

PMID: 38482624 DOI: 10.2174/0113816128296105240305110312.

The NLRP3 molecule influences the therapeutic effects of mesenchymal stem cells through Glut1-mediated energy metabolic reprogramming.

Chen J, Xie S, Qiu D, Xie M, Wu M, Li X J Adv Res. 2023; 65:125-136.

PMID: 38070595 PMC: 11519012. DOI: 10.1016/j.jare.2023.12.006.

The role of amino acid metabolism in inflammatory bowel disease and other inflammatory diseases.

Zheng X, Zhu Y, Zhao Z, Chu Y, Yang W Front Immunol. 2023; 14:1284133.

PMID: 37936710 PMC: 10626463. DOI: 10.3389/fimmu.2023.1284133.

References

Hommes D, Colombel J, Emery P, Greco M, Sandborn W . Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012; 6 Suppl 2:S224-34. DOI: 10.1016/S1873-9946(12)60502-9. View

Duijvestein M, Vos A, Roelofs H, Wildenberg M, Wendrich B, Verspaget H . Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010; 59(12):1662-9. DOI: 10.1136/gut.2010.215152. View

Lowenthal R, Cohen M, Atkinson K, BIGGS J . Apparent cure of rheumatoid arthritis by bone marrow transplantation. J Rheumatol. 1993; 20(1):137-40. View

Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S . Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002; 30(1):42-8. DOI: 10.1016/s0301-472x(01)00769-x. View

Oyama Y, Craig R, Traynor A, Quigley K, Statkute L, Halverson A . Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology. 2005; 128(3):552-63. DOI: 10.1053/j.gastro.2004.11.051. View

Anderson C, Boucher G, Lees C, Franke A, DAmato M, Taylor K . Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011; 43(3):246-52. PMC: 3084597. DOI: 10.1038/ng.764. View

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

ZuK P, Zhu M, Ashjian P, De Ugarte D, Huang J, Mizuno H . Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002; 13(12):4279-95. PMC: 138633. DOI: 10.1091/mbc.e02-02-0105. View

Zand A, van Deen W, Inserra E, Hall L, Kane E, Centeno A . Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact. Inflamm Bowel Dis. 2015; 21(7):1623-30. DOI: 10.1097/MIB.0000000000000399. View

10.

Sullivan K, McDonald G . Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology. 1998; 114(3):433-40. DOI: 10.1016/s0016-5085(98)70525-6. View

11.

Le Blanc K, Tammik C, Rosendahl K, Zetterberg E, Ringden O . HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003; 31(10):890-6. DOI: 10.1016/s0301-472x(03)00110-3. View

12.

Spence J, Mayhew C, Rankin S, Kuhar M, Vallance J, Tolle K . Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2010; 470(7332):105-9. PMC: 3033971. DOI: 10.1038/nature09691. View

13.

Ankrum J, Ong J, Karp J . Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014; 32(3):252-60. PMC: 4320647. DOI: 10.1038/nbt.2816. View

14.

Lazebnik L, Lychkova A, Knyazev O . Treatment of experimental ulcerative colitis. Bull Exp Biol Med. 2012; 153(6):889-92. DOI: 10.1007/s10517-012-1852-z. View

15.

Shah N, Kammermeier J, Elawad M, Glocker E . Interleukin-10 and interleukin-10-receptor defects in inflammatory bowel disease. Curr Allergy Asthma Rep. 2012; 12(5):373-9. DOI: 10.1007/s11882-012-0286-z. View

16.

Ciccocioppo R, Bernardo M, Sgarella A, Maccario R, Avanzini M, Ubezio C . Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut. 2011; 60(6):788-98. DOI: 10.1136/gut.2010.214841. View

17.

Nauta A, Westerhuis G, Kruisselbrink A, Lurvink E, Willemze R, Fibbe W . Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood. 2006; 108(6):2114-20. PMC: 1895546. DOI: 10.1182/blood-2005-11-011650. View

18.

Sallerfors B, Olofsson T . Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by adherent monocytes measured by quantitative immunoassays. Eur J Haematol. 1992; 49(4):199-207. DOI: 10.1111/j.1600-0609.1992.tb00047.x. View

19.

de la Portilla F, Alba F, Garcia-Olmo D, Herrerias J, Gonzalez F, Galindo A . Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis. 2012; 28(3):313-23. DOI: 10.1007/s00384-012-1581-9. View

20.

Bekkum D . Immune ablation and stem-cell therapy in autoimmune disease. Experimental basis for autologous stem-cell transplantation. Arthritis Res. 2000; 2(4):281-4. PMC: 130010. DOI: 10.1186/ar103. View